KEMUDI - Foto ilustrasi. Shio Kerbau mengambil kemudi pada Senin 24 Februari 2025. Lalu hoki shio Kerbau - Tikus - Naga - Kelinci - Monyet? TRIBUNMANADO.CO.ID - Shio Kerbau mengambil kemudi pada Senin ...

Sebuah mobil seringkali digunakan bergantian dengan beberapa anggota keluarga. Hal ini membuat pengaturan kursi kemudi seringkali berubah dan memakan waktu untuk diatur kembali. Bagi keluarga modern ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...

WARTAKOTALIVE.COM, JAKARTA - Publik mengkritik keberadaan sejumlah tokoh yang berada di balik kemudi Badan Pengelola Investasi (BPI) Danantara. Pasalnya, tokoh-tokoh tersebut pernah tersangkut kasus ...

Jakarta: Publik mengkritik keberadaan sejumlah tokoh yang berada di balik kemudi Badan Pengelola Investasi (BPI) Danantara. Pasalnya, tokoh-tokoh tersebut pernah tersangkut kasus korupsi seperti ...

Di sisi lain, publik mengkritik keberadaan sejumlah tokoh yang berada di balik kemudi Badan Pengelola Investasi (BPI) Danantara. Pasalnya, tokoh-tokoh tersebut pernah tersangkut kasus korupsi seperti ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid concerns that jurors might be influenced by controversy this month around ...

Merck (NYSE:MRK) and a plaintiff who is suing the drugmaker over allegations that the Gardasil HPV vaccine she received as a teen caused her heart issues and nerve pain have agreed to adjourn the ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...